Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Hepatocellular carcinoma macroscopic gross appearance on imaging: predictor of outcome after transarterial chemoembolization in a real-life multicenter French cohort.

Adhoute X, Pénaranda G, Raoul JL, Pietri O, Bronowicki JP, Castellani P, Perrier H, Monnet O, Bayle O, Oules V, Pol B, Beaurain P, Muller C, Cassagneau P, Bourlière M.

Eur J Gastroenterol Hepatol. 2019 Apr 29. doi: 10.1097/MEG.0000000000001420. [Epub ahead of print]

PMID:
31045613
2.

Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.

Ni JY, Kong J, Sun HL, Chen YT, Luo JH, Wang WD, Chen D, Jiang XY, Xu LF.

Acad Radiol. 2018 Apr;25(4):423-429. doi: 10.1016/j.acra.2017.10.018. Epub 2017 Nov 29.

PMID:
29198946
3.

Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study.

Chen R, Gan Y, Ge N, Chen Y, Wang Y, Zhang B, Wang Y, Ye S, Ren Z.

J Vasc Interv Radiol. 2016 Dec;27(12):1829-1836. doi: 10.1016/j.jvir.2016.06.010. Epub 2016 Aug 21.

PMID:
27553917
4.

Impact of Tumor Factors on Survival in Patients with Hepatocellular Carcinoma Classified Based on Kinki Criteria Stage B2.

Arizumi T, Minami T, Chishina H, Kono M, Takita M, Yada N, Hagiwara S, Minami Y, Ida H, Ueshima K, Kamata K, Minaga K, Komeda Y, Takenaka M, Sakurai T, Watanabe T, Nishida N, Kudo M.

Dig Dis. 2017;35(6):583-588. doi: 10.1159/000480186. Epub 2017 Oct 17.

PMID:
29040991
6.

Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma.

Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, Mulcahy MF, Baker T, Abecassis M, Miller FH, Yaghmai V, Sato K, Desai K, Thornburg B, Benson AB, Rademaker A, Ganger D, Kulik L, Lewandowski RJ.

Gastroenterology. 2016 Dec;151(6):1155-1163.e2. doi: 10.1053/j.gastro.2016.08.029. Epub 2016 Aug 27.

7.

Single- versus Triple-Drug Chemoembolization for Hepatocellular Carcinoma: Comparing Outcomes by Toxicity, Imaging Response, and Survival.

Mouli SK, Hickey R, Thornburg B, Sato KT, Desai K, Gabr A, Kallini JR, Niemeri H, Kircher S, Mulcahy MF, Benson Iii AB, Gupta R, Salem R, Lewandowski RJ.

J Vasc Interv Radiol. 2016 Sep;27(9):1279-1287. doi: 10.1016/j.jvir.2016.01.135. Epub 2016 Apr 6.

PMID:
27062355
8.

Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses.

Choi GH, Shim JH, Kim MJ, Ryu MH, Ryoo BY, Kang YK, Shin YM, Kim KM, Lim YS, Lee HC.

Radiology. 2013 Nov;269(2):603-11. doi: 10.1148/radiol.13130150. Epub 2013 Jul 17.

PMID:
23864102
9.

Validation of Newly Proposed Time to Transarterial Chemoembolization Progression in Intermediate-Stage Hepatocellular Carcinoma Cases.

Izumoto H, Hiraoka A, Ishimaru Y, Murakami T, Kitahata S, Ueki H, Aibiki T, Okudaira T, Miyamoto Y, Yamago H, Iwasaki R, Tomida H, Mori K, Kishida M, Tsubouchi E, Miyata H, Ninomiya T, Kawasaki H, Hirooka M, Matsuura B, Abe M, Hiasa Y, Michitaka K, Kudo M.

Oncology. 2017;93 Suppl 1:120-126. doi: 10.1159/000481242. Epub 2017 Dec 20.

10.

Conventional Ethiodized Oil Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma: Contemporary Single-Center Review of Clinical Outcomes.

Casadaban LC, Minocha J, Bui JT, Knuttinen MG, Ray CE Jr, Gaba RC.

AJR Am J Roentgenol. 2016 Mar;206(3):645-54. doi: 10.2214/AJR.15.14758.

PMID:
26901023
11.

The Overall Survival of Patients with Hepatocellular Carcinoma Correlates with the Newly Defined Time to Progression after Transarterial Chemoembolization.

Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, Takita M, Yada N, Hagiwara S, Minami Y, Ida H, Komeda Y, Takenaka M, Sakurai T, Watanabe T, Nishida N, Kudo M.

Liver Cancer. 2017 Jun;6(3):227-235. doi: 10.1159/000475777. Epub 2017 May 9.

12.

Association of Sustained Response Duration With Survival After Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma.

Zhang Y, Zhang M, Chen M, Mei J, Xu L, Guo R, Lin X, Li J, Peng Z.

JAMA Netw Open. 2018 Oct 5;1(6):e183213. doi: 10.1001/jamanetworkopen.2018.3213.

13.

Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.

Li L, Zhao W, Wang M, Hu J, Wang E, Zhao Y, Liu L.

BMC Gastroenterol. 2018 Sep 4;18(1):138. doi: 10.1186/s12876-018-0849-0. Review.

14.

Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.

Kloeckner R, Weinmann A, Prinz F, Pinto dos Santos D, Ruckes C, Dueber C, Pitton MB.

BMC Cancer. 2015 Jun 10;15:465. doi: 10.1186/s12885-015-1480-x.

15.

A Modified Model for Assessment for Retreatment with Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients.

Chen L, Ni CF, Chen SX, Cao JM, Zhu HD, Guo JH, Zhu GY, Zhong BY, Ding W, He SC, Deng G, Teng GJ.

J Vasc Interv Radiol. 2016 Sep;27(9):1288-1297. doi: 10.1016/j.jvir.2015.12.016. Epub 2016 Mar 21.

PMID:
27013402
16.

Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.

Biolato M, Gallusi G, Iavarone M, Cabibbo G, Racco S, De Santis A, Corte CD, Maida M, Attili AF, Sangiovanni A, Cammà C, La Torre G, Gasbarrini A, Grieco A.

Ann Hepatol. 2018 January-February;17(1):110-118. doi: 10.5604/01.3001.0010.7542.

17.

NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization.

Adhoute X, Pénaranda G, Raoul JL, Bollon E, Pol B, Letreut YP, Perrier H, Bayle O, Monnet O, Beaurain P, Muller C, Hardwigsen J, Lefolgoc G, Castellani P, Bronowicki JP, Bourlière M.

Eur J Gastroenterol Hepatol. 2017 Jun;29(6):706-715. doi: 10.1097/MEG.0000000000000852.

PMID:
28195873
19.

Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.

Chen RX, Gan YH, Ge NL, Chen Y, Ma H, Wang Y, Zhang BH, Wang YH, Ye SL, Luo JF, Ren ZG.

J Gastroenterol Hepatol. 2016 Feb;31(2):442-9. doi: 10.1111/jgh.13077.

PMID:
26259976
20.

Conventional versus drug-eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size.

Lee YK, Jung KS, Kim DY, Choi JY, Kim BK, Kim SU, Park JY, Ahn SH, Han KH, Kim GM, Kim MD, Park SI, Won JY, Lee DY.

J Gastroenterol Hepatol. 2017 Feb;32(2):487-496. doi: 10.1111/jgh.13501.

PMID:
27503585

Supplemental Content

Support Center